EPO intends to grant Alzinova a European patent for the ALZ-201 monoclonal antibody
The European Patent Office (EPO) has informed Alzinova that it intends to grant the company a European patent for the monoclonal antibody ALZ-201.
The antibody was developed using the company’s AβCC technology, which specifically stabilizes the “oligomers” that are central to the Alzheimer’s disease process. The AβCC technology thus enables drug development towards the oligomers. ALZ-201 is currently in validation phase, and is being investigated as a potential diagnostic tool for detecting Alzheimer’s disease patients at an early stage of the disease.
When finally issued, the patent will strengthen Alzinova’s intellectual property.
The antibody patent has previously been approved in the USA.